The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Maintaining remission in AML and improving long-term survival in patients who do not receive HSCT
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses strategies to maintain remission in acute myeloid leukemia (AML) and improve long-term survival in patients who do not receive hematopoietic stem cell transplantation (HSCT). She mentions the use of measurable residual disease (MRD) to predict which patients will relapse, eradicating MRD with azacitidine, and targeted therapies such as FLT3, IDH1, and IDH2 inhibitors. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
